Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

(2017) John P Neoptolemos et al.   LANCET

Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy

(2016) Kathleen K. Christians et al.   SURGERY

Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma – A population-based cohort study

(2015) Knut J. Labori et al.   ACTA ONCOLOGICA

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) M. Ducreux et al.   ANNALS OF ONCOLOGY

Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer

(2015) Cristina R. Ferrone et al.   ANNALS OF SURGERY

Pathology reporting of pancreatic cancer following neoadjuvant therapy: Challenges and uncertainties

(2015) C. Verbeke et al.   CANCER TREATMENT REVIEWS

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study

(2014) Juan W. Valle et al.   JOURNAL OF CLINICAL ONCOLOGY

Pancreatic Adenocarcinoma: Treating a Systemic Disease With Systemic Therapy

(2014) D. P. Sohal et al.   JNCI-Journal of the National Cancer Institute

Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: A consensus statement by the International Study Group on Pancreatic Surgery (ISGPS)

(2014) Johanna A.M.G. Tol et al.   SURGERY

Postoperative Complications Reduce Adjuvant Chemotherapy Use in Resectable Pancreatic Cancer

(2013) Ryan P. Merkow et al.   ANNALS OF SURGERY

Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival

(2013) Ching-Wei D. Tzeng et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy

(2012) Ching-Wei D. Tzeng et al.   ANNALS OF SURGICAL ONCOLOGY

Improving survival following surgery for pancreatic ductal adenocarcinoma – A ten-year experience

(2012) D. Hoem et al.   EJSO

European cancer mortality predictions for the year 2011

(2011) M. Malvezzi et al.   ANNALS OF ONCOLOGY

Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three Decades

(2011) Jordan M. Winter et al.   ANNALS OF SURGICAL ONCOLOGY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bile leakage after hepatobiliary and pancreatic surgery: A definition and grading of severity by the International Study Group of Liver Surgery

(2011) Moritz Koch et al.   SURGERY

Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection

(2010) John P. Neoptolemos et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Pancreatic surgery: Evolution at a high-volume center

(2010) Kathryn M. Ziegler et al.   SURGERY

The Clavien-Dindo Classification of Surgical Complications

(2009) Pierre A. Clavien et al.   ANNALS OF SURGERY